1887

Abstract

Low levels of the vitamin D-regulated antimicrobial peptide cathelicidin (LL-37) may negatively impact the immune status of human immunodeficiency virus-1 (HIV-1) infected individuals (HIV+). We compared plasma LL-37 levels in healthy controls (HIV−) and HIV+ individuals on or off antiretroviral therapies (ARTs) (ART+ and ART−, respectively), and evaluated the relationship between vitamin D and LL-37 levels. In this cross-sectional study, levels of LL-37, 25-hydroxycholecalciferol [25(OH)D] and 1,25-dihydroxycholecalciferol [1,25(OH)D] were measured from an initial cohort of 18 healthy controls and 10 HIV+/ART− individuals. Because this cohort lacked HIV+/ART+ subjects, LL-37 was also quantified from a second cohort of 10 HIV+/ART− and 13 HIV+/ART+ individuals. LL-37 levels were significantly lower in the HIV+/ART− group compared to the healthy controls ( = 0.01). A direct relationship was observed between LL-37 and both 25(OH)D and 1,25(OH)D. The level of 25(OH)D was predictive of higher LL-37 ( = 0.04) and for any given level of 25(OH)D, HIV+/ART− subjects averaged 20 % lower LL-37 compared to the healthy controls ( = 0.045). For any given level of 1,25(OH)D, HIV+/ART− subjects averaged 25 % lower LL-37 compared to the healthy controls ( = 0.018), although 1,25(OH)D was not predictive of higher LL-37 ( = 0.28). Finally, LL-37 levels were significantly lower in the HIV+/ART− group compared to the HIV+/ART+ group from the second cohort ( = 0.045). Untreated HIV infection may contribute to lower LL-37 levels, independent of vitamin D levels. ART treatment may potentially mitigate this decrease in LL-37 levels.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.070888-0
2014-07-01
2019-10-22
Loading full text...

Full text loading...

/deliver/fulltext/jmm/63/7/997.html?itemId=/content/journal/jmm/10.1099/jmm.0.070888-0&mimeType=html&fmt=ahah

References

  1. Allavena C., Delpierre C., Cuzin L., Rey D., Viget N., Bernard J., Guillot P., Duvivier C., Billaud E., Raffi F.. ( 2012;). High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs. . J Antimicrob Chemother 67:, 2222–2230. [CrossRef][PubMed]
    [Google Scholar]
  2. Bang U. C., Shakar S. A., Hitz M. F., Jespersen M. S., Andersen O., Nielsen S. D., Jensen J. E.. ( 2010;). Deficiency of 25-hydroxyvitamin D in male HIV-positive patients: a descriptive cross-sectional study. . Scand J Infect Dis 42:, 306–310. [CrossRef][PubMed]
    [Google Scholar]
  3. Belec L., Meillet D., Gaillard O., Prazuck T., Michel E., Ngondi Ekome J., Pillot J.. ( 1995;). Decreased cervicovaginal production of both IgA1 and IgA2 subclasses in women with AIDS. . Clin Exp Immunol 101:, 100–106. [CrossRef][PubMed]
    [Google Scholar]
  4. Bhan I., Camargo C. A. Jr, Wenger J., Ricciardi C., Ye J., Borregaard N., Thadhani R.. ( 2011;). Circulating levels of 25-hydroxyvitamin D and human cathelicidin in healthy adults. . J Allergy Clin Immunol 127:, 1302–1304. [CrossRef][PubMed]
    [Google Scholar]
  5. Campbell G. R., Spector S. A.. ( 2012a;). Autophagy induction by vitamin D inhibits both Mycobacterium tuberculosis and human immunodeficiency virus type 1. . Autophagy 8:, 1523–1525. [CrossRef][PubMed]
    [Google Scholar]
  6. Campbell G. R., Spector S. A.. ( 2012b;). Vitamin D inhibits human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection in macrophages through the induction of autophagy. . PLoS Pathog 8:, e1002689. [CrossRef][PubMed]
    [Google Scholar]
  7. Crutchley R. D., Gathe J. Jr, Mayberry C., Trieu A., Abughosh S., Garey K. W.. ( 2012;). Risk factors for vitamin D deficiency in HIV-infected patients in the south central United States. . AIDS Res Hum Retroviruses 28:, 454–459.[PubMed]
    [Google Scholar]
  8. Dixon B. M., Barker T., McKinnon T., Cuomo J., Frei B., Borregaard N., Gombart A. F.. ( 2012;). Positive correlation between circulating cathelicidin antimicrobial peptide (hCAP18/LL-37) and 25-hydroxyvitamin D levels in healthy adults. . BMC Res Notes 5:, 575. [CrossRef][PubMed]
    [Google Scholar]
  9. Dürr U. H., Sudheendra U. S., Ramamoorthy A.. ( 2006;). LL-37, the only human member of the cathelicidin family of antimicrobial peptides. . Biochim Biophys Acta 1758:, 1408–1425. [CrossRef][PubMed]
    [Google Scholar]
  10. Fowler M. G., Melnick S. L., Mathieson B. J.. ( 1997;). Women and HIV. Epidemiology and global overview. . Obstet Gynecol Clin North Am 24:, 705–729. [CrossRef][PubMed]
    [Google Scholar]
  11. Goleva E., Searing D. A., Jackson L. P., Richers B. N., Leung D. Y.. ( 2012;). Steroid requirements and immune associations with vitamin D are stronger in children than adults with asthma. . J Allergy Clin Immunol 129:, 1243–1251. [CrossRef][PubMed]
    [Google Scholar]
  12. Gombart A. F., Bhan I., Borregaard N., Tamez H., Camargo C. A. Jr, Koeffler H. P., Thadhani R.. ( 2009;). Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. . Clin Infect Dis 48:, 418–424. [CrossRef][PubMed]
    [Google Scholar]
  13. Howell A. L., Groveman D. S., Wallace P. K., Fanger M. W.. ( 1997;). HIV-1-infected monocytes and monocyte-derived macrophages are impaired in their ability to produce superoxide radicals. . Int J Clin Lab Res 27:, 111–117. [CrossRef][PubMed]
    [Google Scholar]
  14. Jeng L., Yamshchikov A. V., Judd S. E., Blumberg H. M., Martin G. S., Ziegler T. R., Tangpricha V.. ( 2009;). Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. . J Transl Med 7:, 28. [CrossRef][PubMed]
    [Google Scholar]
  15. Levinson P., Choi R. Y., Cole A. L., Hirbod T., Rhedin S., Payne B., Guthrie B. L., Bosire R., Cole A. M.. & other authors ( 2012;). HIV-neutralizing activity of cationic polypeptides in cervicovaginal secretions of women in HIV-serodiscordant relationships. . PLoS ONE 7:, e31996. [CrossRef][PubMed]
    [Google Scholar]
  16. Mahmood S. A. I.. ( 2010;). TB and HIV/AIDS in Bangladesh. . J AIDS HIV Res 2:, 66–78.
    [Google Scholar]
  17. Redd S. C., Rutherford G. W. III, Sande M. A., Lifson A. R., Hadley W. K., Facklam R. R., Spika J. S.. ( 1990;). The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. . J Infect Dis 162:, 1012–1017. [CrossRef][PubMed]
    [Google Scholar]
  18. Segal L. N., Methé B. A., Nolan A., Hoshino Y., Rom W. N., Dawson R., Bateman E., Weiden M. D.. ( 2011;). HIV-1 and bacterial pneumonia in the era of antiretroviral therapy. . Proc Am Thorac Soc 8:, 282–287. [CrossRef][PubMed]
    [Google Scholar]
  19. Twigg H. L. III, Spain B. A., Soliman D. M., Bowen L. K., Heidler K. M., Wilkes D. S.. ( 1996;). Impaired IgG production in the lungs of HIV-infected individuals. . Cell Immunol 170:, 127–133. [CrossRef][PubMed]
    [Google Scholar]
  20. Van Den Bout-Van Den Beukel C. J., Fievez L., Michels M., Sweep F. C., Hermus A. R., Bosch M. E., Burger D. M., Bravenboer B., Koopmans P. P., Van Der Ven A. J.. ( 2008;). Vitamin D deficiency among HIV type 1-infected individuals in The Netherlands: effects of antiretroviral therapy. . AIDS Res Hum Retroviruses 24:, 1375–1382. [CrossRef][PubMed]
    [Google Scholar]
  21. Velasco M., Castilla V., Sanz J., Gaspar G., Condes E., Barros C., Cervero M., Torres R., Guijarro C..COMESEM Cohort ( 2009;). Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. . J Acquir Immune Defic Syndr 50:, 148–152. [CrossRef][PubMed]
    [Google Scholar]
  22. Vescini F., Cozzi-Lepri A., Borderi M., Re M. C., Maggiolo F., De Luca A., Cassola G., Vullo V., Carosi G.. & other authors ( 2011;). Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. . J Acquir Immune Defic Syndr 58:, 163–172. [CrossRef][PubMed]
    [Google Scholar]
  23. Viard J. P., Souberbielle J. C., Kirk O., Reekie J., Knysz B., Losso M., Gatell J., Pedersen C., Bogner J. R.. & other authors ( 2011;). Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. . AIDS 25:, 1305–1315. [CrossRef][PubMed]
    [Google Scholar]
  24. Wang T. T., Nestel F. P., Bourdeau V., Nagai Y., Wang Q., Liao J., Tavera-Mendoza L., Lin R., Hanrahan J. W.. & other authors ( 2004;). Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. . J Immunol 173:, 2909–2912. [CrossRef][PubMed]
    [Google Scholar]
  25. Yamshchikov A. V., Kurbatova E. V., Kumari M., Blumberg H. M., Ziegler T. R., Ray S. M., Tangpricha V.. ( 2010;). Vitamin D status and antimicrobial peptide cathelicidin (LL-37) concentrations in patients with active pulmonary tuberculosis. . Am J Clin Nutr 92:, 603–611. [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.070888-0
Loading
/content/journal/jmm/10.1099/jmm.0.070888-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error